ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY

Milgrom A.; Min S.; Duhon G.; Lee K.; Glueck C. J.; Wang P.

首页> 外文期刊>Journal of investigative medicine >ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY

【24h】

ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY

机译：1090例高胆固醇患者的PCSK9抑制剂治疗的资格提到了具有LDL胆固醇的区域胆固醇治疗中心，= 70mg / DL，尽管最大耐受性胆固醇降低治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of investigative medicine》 |2017年第4期|共1页
作者
Milgrom A.; Min S.; Duhon G.; Lee K.; Glueck C. J.; Wang P.;
展开▼
作者单位

Jewish Hosp Internal Med Cincinnati OH USA;

Jewish Hosp Internal Med Cincinnati OH USA;

Jewish Hosp Internal Med Cincinnati OH USA;

Jewish Hosp Internal Med Cincinnati OH USA;

Jewish Hosp Internal Med Cincinnati OH USA;

Jewish Hosp Internal Med Cincinnati OH USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY [J] . Milgrom A., Min S., Duhon G., Journal of investigative medicine . 2017,第4期

机译：1090例高胆固醇患者的PCSK9抑制剂治疗的资格提到了具有LDL胆固醇的区域胆固醇治疗中心，= 70mg / DL，尽管最大耐受性胆固醇降低治疗
2. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy [J] . Vybhav Jetty, Charles J Glueck, Kevin Lee, Vascular Health and Risk Management . 2017,第4期

机译：尽管最大耐受性降低LDL胆固醇的疗法，但仍向LDL胆固醇≥70 mg / dL的地区胆固醇治疗中心推荐的1090名高胆固醇血症患者接受alirocumab或evolocumab治疗
3. ELIGIBILITY FOR PCSK9 TREATMENT IN 734 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL >= 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY [J] . Shah P., Glueck C. J., Goldenberg N., Journal of investigative medicine . 2016,第4期

机译：在LDL胆固醇大于等于70 MG / DL的区域性胆固醇治疗中心治疗的734例胆固醇高的患者中PCSK9治疗的合格率
4. SORPTION PROPERTIES OF CHOLESTEROL-LOWERING (STATIN) PHARMACEUTICALS TO BIOSOLIDS IN WASTEWATER TREATMENT SYSTEMS [C] . Karl J.Ottmar, James A. Smith, Megan Fuller American Chemical Society Division of Environmental Chemistry Symposium . 2008

机译：胆固醇降低（Satisin）药物在废水处理系统中生物糖的吸附性能
5. An Investigation into Statins, PCSK9 Inhibitors, and Other Current Cholesterol Treatments [D] . Kiley, Mark E. 2018

机译：他汀类药物，PCSK9抑制剂和其他当前胆固醇治疗的研究
6. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy [O] . Vybhav Jetty, Charles J Glueck, Kevin Lee, 2017

机译：尽管耐受性最大的降低LDL胆固醇的疗法但仍向LDL胆固醇≥70 mg / dL的地区胆固醇治疗中心推荐的1090名高胆固醇血症患者接受alirocumab或evolocumab治疗
7. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ge;70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy [O] . Vybhav Jetty, Charles Glueck, Kevin Lee, 2017

机译：1090中的Alirocumab或Evolocumab治疗的资格在1090例高胆固醇患者中提到了含有LDL胆固醇≥70mg/ dl的区域胆固醇治疗中心，尽管最大耐受LDL-胆固醇降低治疗

ELIGIBILITY FOR PCSK9 INHIBITOR TREATMENT IN 1090 HYPERCHOLESTEROLEMIC PATIENTS REFERRED TO A REGIONAL CHOLESTEROL TREATMENT CENTER WITH LDL CHOLESTEROL = 70 MG/DL DESPITE MAXIMAL TOLERATED CHOLESTEROL LOWERING THERAPY

著录项

相似文献

相关主题

期刊订阅